Repeated Favorable Responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma.
10.4046/trd.2013.74.3.129
- Author:
Eun Young KIM
1
;
Yoon Hee KIM
;
Hee Jung BAN
;
In Jae OH
;
Yong Soo KWON
;
Kyu Sik KIM
;
Yu Il KIM
;
Sung Chul LIM
;
Young Chul KIM
Author Information
1. Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Hwasun, Korea. droij@chonnam.ac.kr
- Publication Type:Case Report
- Keywords:
Adenocarcinoma;
Receptor, Epidermal Growth Factor;
Gefitinib
- MeSH:
Adenocarcinoma;
Cisplatin;
Constriction;
Deoxycytidine;
Epidermal Growth Factor;
Female;
Glutamates;
Guanine;
Humans;
Lung;
Lung Neoplasms;
Phosphotransferases;
Quinazolines;
Receptor, Epidermal Growth Factor;
Recurrence;
Retreatment;
Pemetrexed
- From:Tuberculosis and Respiratory Diseases
2013;74(3):129-133
- CountryRepublic of Korea
- Language:English
-
Abstract:
The presence of epidermal growth factor receptor (EGFR) mutation is a prognostic and predictive marker for EGFR-tyrosine kinase inhibitor (TKI) therapy. However, inevitably, relapse occurs due to the development of acquired resistance, such as T790M mutation. We report a case of repeated responses to EGFR-TKIs in a never-smoked woman with adenocarcinoma. After six cycles of gemcitabine and cisplatin, the patient was treated by gefitinib for 4 months until progression. Following the six cycles of third-line pemetrexed, gefitinib retreatment was initiated and continued with a partial response for 6 months. After progression, she was recruited for an irreversible EGFR inhibitor trial, and the time to progression was 11 months. Although EGFR direct sequencing on the initial diagnostic specimen revealed a wild-type, we performed a rebiopsy from the progressed subcarinal node at the end of the trial. The result of peptide nucleic acid clamping showed L858R/L861Q.
